The diabetes-associated K+ channel TALK-2 controls human beta cell endoplasmic reticulum Ca2+ handling, which promotes basal insulin release and limits glucose-stimulated insulin secretion
Das diabetesassoziierte K+-Kanals TALK-2 steuert die ER-Ca2+-Handhabung menschlicher Betazellen, fördert die basale Insulinfreisetzung und begrenzt die glukosestimulierte Insulinsekretion
Diabetologia · 2026-06 · 69 (6) · 1581-1599
DOI: 10.1007/s00125-026-06683-9 ↗Auf einen Blick
TALK-2 beeinflusste in humanen Betazellen die Ca2+-Homöostase im endoplasmatischen Retikulum und die Insulinsekretion. Höhere TALK-2-Aktivität war mit mehr basaler und weniger glukosestimulierter Insulinfreisetzung verbunden.
Fragestellung
Welche Funktion hat TALK-2 in der Ca2+-Homöostase humaner Betazellen und wie wirkt sich das auf die Insulinsekretion aus?
Methode
Lokalisations- und Funktionsanalyse von TALK-2 in einer induzierbaren Zelllinie und in primären humanen Betazellen; Messung von zytoplasmatischem Ca2+, ER-Ca2+, ER-Membranpotenzial, K+-Strömen und Insulinsekretion; TALK-2-Knockdown per Adenovirus-shRNA.
Ergebnisse
TALK-2 lokalisierte an Plasma- und ER-Membran und bildete funktionelle Kanäle an der ER-Membran. TALK-2 erhöhte die Ca2+-Freisetzung aus dem ER, verringerte ER-Ca2+-Speicher und steigerte basales zytoplasmatisches Ca2+. Knockdown erhöhte ER-Ca2+-Speicher und GSIS.
Schlussfolgerung der Autor:innen
Die Daten sprechen dafür, dass TALK-2 an der ER-Membran die elektrische Triebkraft für ER-Ca2+-Freisetzung erhöht, glukosestimulierten Ca2+-Einstrom begrenzt und GSIS vermindert. Eine erhöhte TALK-2-Aktivität könnte das Typ-2-Diabetes-Risiko erhöhen.
Kernaussagen
- TALK-2 sitzt an der Plasma- und ER-Membran humaner Betazellen
- TALK-2 fördert ER-Ca2+-Leak und erhöht basales zytoplasmatisches Ca2+
- TALK-2-Knockdown senkte basale Insulinsekretion und steigerte GSIS
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, online erschienen am 25.02.2026. Verfasst von Jordyn R Dobson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA. Hauptthemen laut MEDLINE: Endoplasmic Reticulum, Insulin-Secreting Cells, Insulin, Calcium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leona M. and Harry B. Helmsley Charitable Trust, Horizon 2020 Framework Programme, NIDDK NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/hypothesis The two-pore domain K + channel TWIK1-related alkalinisation-activated K + channel 2 (TALK-2) is encoded by KCNK17 , which is one of the most abundant beta cell K + channel transcripts that also shows high islet expression specificity. Polymorphisms that increase islet KNCK17 expression or result in TALK-2 gain-of-function are associated with a predisposition for developing type 2 diabetes. However, there is a gap in knowledge of the beta cell function(s) of TALK-2. As K + channels typically control beta cell Ca 2+ handling, we aimed to examine the TALK-2 channel control of beta cell Ca 2+ homeostasis and the resulting impact on insulin secretion.
Methods
Localisation of TALK-2 was evaluated with immunofluorescent staining as well as TALK-2-GFP construct co-expressed with intracellular markers. TALK-2 function was evaluated by measuring changes in cytoplasmic Ca 2+ (Ca 2+ C ), endoplasmic reticulum Ca 2+ (Ca 2+ ER ), ER membrane potential ( V m ), K + currents and insulin secretion in a TALK-2 inducible cell line and/or primary human beta cells with adenoviral-mediated shRNA knockdown (KD) of TALK-2 or scramble shRNA.
Results
TALK-2 protein localised to the plasma membrane and ER membrane, and formed functional channels on the ER membrane. Ca 2+ ER release was accelerated by TALK-2 (slope for TALK-2-expressing cells vs controls: 14.8 ± 0.7 vs 8.9 ± 1.3, respectively, shown as mean ± SE), which reduced Ca 2+ ER storage (ΔCa 2+ ER amplitude: TALK-2-expressing cells reduced by 25 ± 5%) and increased basal relative Ca 2+ C (fold increase by 12 ± 2%). Furthermore, TALK-2 diminished ER membrane hyperpolarisation following Ca 2+ ER release (Accelerated Sensor of Action Potentials [ASAP3 ER ] amplitude decreased by 20 ± 0.8% in TALK-2-expressing cells), suggesting that TALK-2 strengthens the electrical driving force for Ca 2+ ER leak. In human beta cells, TALK-2-KD increased Ca 2+ ER stores by reducing Ca 2+ ER leak (2.30 ± 0.12 vs controls 2.65 ± 0.14). Moreover, TALK-2-KD reduced beta cell Ca 2+ C at euglycaemic conditions (2.88 ± 0.36 vs controls 3.16 ± 0.36) and increased beta cell Ca 2+ C influx in response to hyperglycaemic conditions (4.07 ± 0.55 vs controls 3.45 ± 0.48). Human pseudoislets with beta cell-specific TALK-2-KD displayed reduced basal insulin secretion (0.266 ± 0.065 vs controls 0.432 ± 0.073) and enhanced glucose-stimulated insulin secretion (GSIS; 85.01 ± 13.96 vs controls 42.53 ± 5.52). Conclusions/interpretation These data support the notion that TALK-2 functions on the human beta cell ER membrane to increase the electrical driving force for beta cell Ca 2+ ER release, reduces glucose-stimulated Ca 2+ influx and limits GSIS. Furthermore, TALK-2-mediated amplification of Ca 2+ ER leak likely enhances basal insulin secretion by increasing Ca 2+ C . Therefore, polymorphisms in KCNK17 that increase TALK-2 activity or expression would be predicted to increase type 2 diabetes risk by blunting beta cell glucose-stimulated Ca 2+ influx, limiting GSIS, promoting Ca 2+ ER leak and elevating basal insulin secretion. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.
- ULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium.
- Interuniversity Institute of Bioinformatics in Brussels, Brussels, Belgium.
- Pharmacognosy, Bioanalysis and Drug Discovery, Pharmacy Faculty, Université Libre de Bruxelles, Brussels, Belgium.
- Division of Endocrinology, ULB Erasmus Hospital, Brussels University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
- WEL Research Institute, Wavre, Belgium.
Förderung
- Leona M. and Harry B. Helmsley Charitable Trust
- Horizon 2020 Framework Programme
- NIDDK NIH HHS
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- NIGMS NIH HHS
- Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture
- Walloon excellence in life sciences and biotechnology
- National Institute of General Medical Sciences
Zitieren
APA
Dobson, J. R., Dadi, P. K., Dickerson, M. T., Nakhe, A. Y., Behera, S., Gibson, S. E., Peachee, S. J., Piron, A., Cnop, M., & Jacobson, D. A. (2026). The diabetes-associated K+ channel TALK-2 controls human beta cell endoplasmic reticulum Ca2+ handling, which promotes basal insulin release and limits glucose-stimulated insulin secretion. Diabetologia, 69(6), 1581-1599. https://doi.org/10.1007/s00125-026-06683-9
Vancouver
Dobson JR, Dadi PK, Dickerson MT, Nakhe AY, Behera S, Gibson SE, et al. The diabetes-associated K+ channel TALK-2 controls human beta cell endoplasmic reticulum Ca2+ handling, which promotes basal insulin release and limits glucose-stimulated insulin secretion. Diabetologia. 2026;69(6):1581-1599. doi:10.1007/s00125-026-06683-9
BibTeX
@article{Dobson2026,
author = {Dobson, Jordyn R and Dadi, Prasanna K and Dickerson, Matthew T and Nakhe, Arya Y and Behera, Soma and Gibson, Shannon E and Peachee, Spencer J and Piron, Anthony and Cnop, Miriam and Jacobson, David A},
title = {The diabetes-associated K+ channel TALK-2 controls human beta cell endoplasmic reticulum Ca2+ handling, which promotes basal insulin release and limits glucose-stimulated insulin secretion},
journal = {Diabetologia},
year = {2026},
volume = {69},
number = {6},
pages = {1581--1599},
doi = {10.1007/s00125-026-06683-9}
}
EUVIMED